The Safety and Efficacy of the Repeated PRRT with [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE in Patients with NET

Figure 2

Tandem [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE therapy: Kaplan–Meier estimators of the progression-free survival after the initial PRRT (PFS I) in relation to the progression-free survival after the repeated PRRT (PFS II).